Yesafili®
ACTIVE PRINCIPLE:
Aflibercept
INDICATION:
Macular edema
retinal vein occlusion
Diabetic retinopathy
degenerative myopia
diabetic complications
DATE:
15/09/2023
STATUS:
Authorized
ACTIVE PRINCIPLE:
Aflibercept
INDICATION:
Macular edema
retinal vein occlusion
Diabetic retinopathy
degenerative myopia
diabetic complications
DATE:
15/09/2023
STATUS:
Authorized